Katherine Esposito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4144656/publications.pdf

Version: 2024-02-01

268 papers

21,939 citations

68 h-index

13087

9854

g-index

272 all docs

272 docs citations

times ranked

272

23190 citing authors

#	Article	IF	CITATIONS
1	Thyroid surgery during the COVID-19 pandemic: results from a systematic review. Journal of Endocrinological Investigation, 2022, 45, 181-188.	1.8	11
2	Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring. Journal of Endocrinological Investigation, 2022, 45, 445-452.	1.8	9
3	Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues. Biomolecules, 2022, 12, 272.	1.8	11
4	The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovascular Diabetology, 2022, 21, 42.	2.7	54
5	Change in Circulating Levels of Endothelial Progenitor Cells and Sexual Function in Women With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	1
6	European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events. Pharmaceuticals, 2022, 15, 677.	1.7	8
7	Impact of COVID-19 on the thyroid gland: an update. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 803-815.	2.6	165
8	Female Sexual Function in Young Women With Type 1 Diabetes and Additional Autoimmune Diseases. Journal of Sexual Medicine, 2021, 18, 219-223.	0.3	4
9	Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis. Thyroid, 2021, 31, 884-894.	2.4	25
10	Neutropenia in patients with hyperthyroidism: Systematic review and metaâ€analysis. Clinical Endocrinology, 2021, 94, 473-483.	1.2	21
11	Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 17.	2.7	27
12	New insights into vitamin D regulation: is there a role for alkaline phosphatase?. Journal of Endocrinological Investigation, 2021, 44, 1891-1896.	1.8	8
13	The residual cardiorenal risk in type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 36.	2.7	14
14	Teleassistance for Patients With Type 1 Diabetes During the COVID-19 Pandemic: Results of a Pilot Study. Journal of Medical Internet Research, 2021, 23, e24552.	2.1	17
15	Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Diabetes Care, 2021, 44, 1353-1360.	4.3	22
16	Medical treatment of thyrotoxicosis. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 113-123.	0.4	3
17	Sexual dysfunctions and short-term glucose variability in young men with type 1 diabetes. Hormones, 2021, 20, 475-482.	0.9	4
18	Antibiotic resistance in diabetic foot infection: how it changed with COVID-19 pandemic in a tertiary care center. Diabetes Research and Clinical Practice, 2021, 175, 108797.	1.1	18

#	Article	IF	Citations
19	Chronothyroidology: Chronobiological Aspects in Thyroid Function and Diseases. Life, 2021, 11, 426.	1.1	5
20	Up and down waves of glycemic control and lower-extremity amputation in diabetes. Cardiovascular Diabetology, 2021, 20, 135.	2.7	7
21	Hypothalamic-Pituitary Autoimmunity and Related Impairment of Hormone Secretions in Chronic Fatigue Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5147-e5155.	1.8	8
22	Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. Cancers, 2021, 13, 4036.	1.7	3
23	Simplification of complex insulin therapy: a story of dogma and therapeutic resignation. Diabetes Research and Clinical Practice, 2021, 178, 108958.	1.1	9
24	Renal and metabolic effects of SGLT-2i and DPP-4i according to basal estimated glomerular filtration rate: Analysis from GIOIA, an observational prospective study. Diabetes Research and Clinical Practice, 2021, 178, 108990.	1.1	0
25	When amputation is not the end of the challenge: A successful therapy for osteomyelitis and soft tissue infection in a patient with typeÂ1 diabetes. Journal of Diabetes Investigation, 2021, , .	1.1	2
26	GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology, 2021, 20, 189.	2.7	104
27	Mediterranean diet in type 2 diabetes: An updated overview of pharmacological activities of cardiometabolic and reproductive outcomes. Current Opinion in Pharmacology, 2021, 60, 27-33.	1.7	6
28	Effects of Mediterranean diet on semen parameters in healthy young adults: a randomized controlled trial. Minerva Endocrinologica, 2021, 45, 280-287.	1.7	8
29	GLP-1 receptor agonists vs. SGLT-2 inhibitors:Âthe gap seems to be leveling off. Cardiovascular Diabetology, 2021, 20, 205.	2.7	18
30	Reply to the letter to the editor by Mungmunpuntipantip et al Journal of Endocrinological Investigation, 2021, , 1.	1.8	2
31	Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular Diabetology, 2021, 20, 210.	2.7	31
32	Maternal and Fetal Outcomes in Women with Diabetes in Pregnancy Treated before and after the Introduction of a Standardized Multidisciplinary Management Protocol. Journal of Diabetes Research, 2021, 2021, 1-11.	1.0	2
33	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovascular Diabetology, 2021, 20, 236.	2.7	63
34	From pump to sink: The hydraulic connection of type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 159, 107772.	1.1	0
35	Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antiâ€hyperglycaemic drug matters?. Diabetes, Obesity and Metabolism, 2020, 22, 149-157.	2.2	21
36	Aging and erectile function. Aging Male, 2020, 23, 1115-1124.	0.9	8

#	Article	IF	Citations
37	Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis. Stroke, 2020, 51, 666-669.	1.0	42
38	Mediterranean Diet and COVID-19: Hypothesizing Potential Benefits in People With Diabetes. Frontiers in Endocrinology, 2020, 11, 574315.	1.5	28
39	Diabetic Foot Problems During the COVID-19 Pandemic in a Tertiary Care Center: The Emergency Among the Emergencies. Diabetes Care, 2020, 43, e123-e124.	4.3	60
40	Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. Cardiovascular Diabetology, 2020, 19, 115.	2.7	33
41	Comment on MÃkimattila et al. Every Fifth Individual With Type 1 Diabetes Suffers From an Additional Autoimmune Disease: A Finnish Nationwide Study. Diabetes Care 2020;43:1041–1047. Diabetes Care, 2020, 43, e105-e105.	4.3	1
42	Glycemic control in people with type 1 diabetes using a hybrid closed loop system and followed by telemedicine during the COVID-19 pandemic in Italy. Diabetes Research and Clinical Practice, 2020, 169, 108440.	1.1	34
43	Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia. Endocrine, 2020, 70, 412-420.	1.1	6
44	Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2020, 43, 1146-1156.	4.3	155
45	Glucose monitoring in diabetes: A suggested algorithm to choice the best treatment option. Diabetes Research and Clinical Practice, 2020, 165, 108242.	1.1	3
46	Sexual dysfunctions in young women with type 1 diabetes and high glucose variability: findings from the METRO study. Journal of Endocrinological Investigation, 2020, 43, 1823-1825.	1.8	3
47	Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2020, 162, 108114.	1.1	29
48	<p>Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 777-784.	1.1	4
49	Impact of Pituitary Autoimmunity and Genetic Disorders on Growth Hormone Deficiency in Children and Adults. International Journal of Molecular Sciences, 2020, 21, 1392.	1.8	5
50	Long-term diabetic complications as predictors of foot ulcers healing failure: A retrospective study in a tertiary-care center. Diabetes Research and Clinical Practice, 2020, 163, 108147.	1.1	13
51	Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A metaâ€analysis with metaâ€regression. Diabetes, Obesity and Metabolism, 2020, 22, 1397-1405.	2.2	27
52	Diabetes and Sexual Disorders. Endocrinology, 2020, , 473-494.	0.1	2
53	Diabetes and Sexual Disorders. Endocrinology, 2020, , 1-22.	0.1	1
54	Type 1 diabetes triggered by covid-19 pandemic: A potential outbreak?. Diabetes Research and Clinical Practice, 2020, 164, 108219.	1.1	45

#	Article	IF	CITATIONS
55	Remission of Pituitary Autoimmunity Induced by Gluten-Free Diet in Patients With Celiac Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2252-2261.	1.8	7
56	GLPâ€1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated metaâ€analysis including the REWIND and PIONEER 6 trials. Diabetes, Obesity and Metabolism, 2019, 21, 2576-2580.	2.2	104
57	Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study. Diabetes Research and Clinical Practice, 2019, 155, 107787.	1.1	3
58	Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovascular Diabetology, 2019, 18, 94.	2.7	30
59	Beyond basal-bolus insulin regimen: Is it still the ultimate chance for therapy in diabetes?. Diabetes Research and Clinical Practice, 2019, 157, 107922.	1.1	5
60	The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 154, 101-115.	1.1	19
61	Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Metaâ€Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. Journal of the American Heart Association, 2019, 8. e012356.	1.6	73
62	The role of autoimmunity in pituitary dysfunction due to traumatic brain injury. Pituitary, 2019, 22, 236-248.	1.6	14
63	Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. Journal of Endocrinological Investigation, 2019, 42, 1165-1169.	1.8	28
64	Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1790-1800.	2.2	28
65	Endocrine rhythms and sport: it is time to take time into account. Journal of Endocrinological Investigation, 2019, 42, 1137-1147.	1.8	13
66	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Frontiers in Endocrinology, 2019, 10, 45.	1.5	94
67	Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. Diabetes, Obesity and Metabolism, 2019, 21, 1081-1087.	2.2	39
68	Diabetes and Sexual Disorders. Endocrinology, 2019, , 1-22.	0.1	0
69	Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care 2017;40:1425ဓ1432. Diabetes Care, 2018, 41, e17-e17.	4.3	5
70	Comment on "The pros and cons of continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin― Authors' reply. Endocrine, 2018, 60, 197-197.	1.1	0
71	Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine, 2018, 61, 23-27.	1.1	36
72	The Effects of Subcutaneous Insulin Infusion Versus Multiple Insulin Injections on Glucose Variability in Young Adults with Type 1 Diabetes: The 2-Year Follow-Up of the Observational METRO Study. Diabetes Technology and Therapeutics, 2018, 20, 117-126.	2.4	24

#	Article	IF	CITATIONS
73	From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome. Journal of Endocrinological Investigation, 2018, 41, 1249-1258.	1.8	101
74	More sugar? No, thank you! The elusive nature of low carbohydrate diets. Endocrine, 2018, 61, 383-387.	1.1	22
75	Continuous glucose monitoring for patients with type 1 diabetes on multiple daily injections of insulin: pros and cons. Endocrine, 2018, 59, 62-65.	1.1	9
76	Sexual function and sex hormones in breast cancer patients. Endocrine, 2018, 60, 510-515.	1.1	13
77	Metabolic syndrome and cancer: "The common soil hypothesis― Diabetes Research and Clinical Practice, 2018, 143, 389-397.	1.1	70
78	Diabetes and Sexual Disorders. Endocrinology, 2018, , 1-22.	0.1	1
79	Free and fixedâ€ratio combinations of basal insulin and GLPâ€1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 2309-2313.	2.2	32
80	Particulate matter air pollution: individual choices for improving cardiometabolic well-being. Endocrine, 2018, 59, 495-498.	1.1	3
81	Diabetes and Sexual Disorders. Endocrinology, 2018, , 473-494.	0.1	0
82	Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?. Endocrine, 2017, 55, 360-365.	1.1	27
83	Premixed insulin regimens in type 2 diabetes: pros. Endocrine, 2017, 55, 45-50.	1.1	7
84	Mediterranean diet for type 2 diabetes: cardiometabolic benefits. Endocrine, 2017, 56, 27-32.	1.1	88
85	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutrition Reviews, 2017, 75, 307-326.	2.6	294
86	Sexual dysfunctions in diabetes: a gender issue. Journal of Diabetes and Its Complications, 2017, 31, 785-786.	1.2	4
87	Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2017, 40, 614-624.	4.3	97
88	Insights into the relationships between diabetes, prediabetes, and cancer. Endocrine, 2017, 56, 231-239.	1.1	63
89	Effect of a Mediterranean diet on endothelial progenitor cells and carotid intima-media thickness in type 2 diabetes: Follow-up of a randomized trial. European Journal of Preventive Cardiology, 2017, 24, 399-408.	0.8	59
90	Ambulatory Glucose Profile Applied to Flash Glucose Monitoring in Real Life: An Expert Opinion. Journal of Diabetes Science and Technology, 2017, 11, 633-634.	1.3	5

#	Article	IF	CITATIONS
91	Can diet prevent diabetes?. Journal of Diabetes and Its Complications, 2017, 31, 288-290.	1.2	10
92	Sexual function in young women with type 1 diabetes: the METRO study. Journal of Endocrinological Investigation, 2017, 40, 169-177.	1.8	36
93	Erectile dysfunction in young men with type 1 diabetes. International Journal of Impotence Research, 2017, 29, 17-22.	1.0	30
94	Intensive Lifestyle Intervention for Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 2494.	3.8	1
95	Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In <i>Standards of Medical Care in Diabetesâ€"2016</i> . Diabetes Care 2016;39(Suppl. 1):S52â€"S59. Diabetes Care, 2016, 39, e86-e87.	4.3	16
96	Mediterranean diet cools down the inflammatory milieu in type 2 diabetes: the MÉDITA randomized controlled trial. Endocrine, 2016, 54, 634-641.	1.1	43
97	Effects of Mediterranean diet on sexual function in people with newly diagnosed type 2 diabetes: The MÃ^DITA trial. Journal of Diabetes and Its Complications, 2016, 30, 1519-1524.	1.2	60
98	Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary, 2016, 19, 625-642.	1.6	94
99	Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends. World Journal of Surgical Oncology, 2016, 14, 149.	0.8	46
100	Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opinion on Drug Safety, 2016, 15, 77-83.	1.0	27
101	Comment on Mita et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care 2016;39:455–464. Diabetes Care, 2016, 39, e102-e103.	4.3	3
102	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. Endocrine, 2016, 54, 32-37.	1.1	1
103	Primary Prevention of Sexual Dysfunction With Mediterranean Diet in Type 2 Diabetes: The MÃ^DITA Randomized Trial. Diabetes Care, 2016, 39, e143-e144.	4.3	22
104	Particulate matter pollutants and risk of type 2 diabetes: a time for concern?. Endocrine, 2016, 51, 32-37.	1.1	54
105	Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine, 2016, 54, 329-341.	1.1	84
106	Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes. Endocrine, 2016, 53, 220-226.	1.1	19
107	Anti-inflammatory Effect of Mediterranean Diet in Type 2 Diabetes Is Durable: 8-Year Follow-up of a Controlled Trial. Diabetes Care, 2016, 39, e44-e45.	4.3	23
108	Longitudinal behavior of autoimmune GH deficiency: from childhood to transition age. European Journal of Endocrinology, 2016, 174, 381-387.	1.9	15

7

#	Article	IF	CITATIONS
109	Mass Treatment With Bariatric Surgery for Type 2 Diabetes Mellitus. JAMA Surgery, 2016, 151, 196.	2.2	O
110	Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine, 2016, 51, 417-428.	1.1	68
111	Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study. Endocrine, 2016, 52, 244-252.	1.1	30
112	Comment on Krul-Poel et al. Effect of Vitamin D Supplementation on Glycemic Control in Patients With Type 2 Diabetes (SUNNY Trial): A Randomized Placebo-Controlled Trial. Diabetes Care 2015;38:1420–1426. Diabetes Care, 2015, 38, e168-e168.	4.3	0
113	The Bitter Taste Receptor Agonist Quinine Reduces Calorie Intake and Increases the Postprandial Release of Cholecystokinin in Healthy Subjects. Journal of Neurogastroenterology and Motility, 2015, 21, 511-519.	0.8	53
114	Lifestyle modifications and erectile dysfunction: what can be expected? Asian Journal of Andrology, 2015, 17, 5.	0.8	89
115	A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open, 2015, 5, e008222.	0.8	368
116	Vitamin D and autoimmunity: what happens in autoimmune polyendocrine syndromes?. Journal of Endocrinological Investigation, 2015, 38, 629-633.	1.8	24
117	Circulating endothelial progenitor cells in type 1 diabetic patients with erectile dysfunction. Endocrine, 2015, 49, 415-421.	1.1	21
118	Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?. Endocrine, 2015, 50, 56-60.	1.1	6
119	Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. Diabetes Research and Clinical Practice, 2015, 108, 157-163.	1.1	39
120	Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?. Journal of Translational Medicine, 2015, 13, 18.	1.8	112
121	A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open, 2015, 5, e005892-e005892.	0.8	63
122	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. BMJ Open Diabetes Research and Care, 2015, 3, e000109.	1.2	7
123	The Link Between Cigarette Smoking and Erectile Dysfunction: A Systematic Review. European Urology Focus, 2015, 1, 39-46.	1.6	23
124	Linking prediabetes and cancer: a complex issue. Diabetologia, 2015, 58, 201-202.	2.9	4
125	Premature Ejaculation is Associated with Glycemic Control in Type 1 Diabetes. Journal of Sexual Medicine, 2015, 12, 93-99.	0.3	18
126	Glucose variability inversely associates with endothelial progenitor cells in type 1 diabetes. Endocrine, 2015, 48, 342-345.	1.1	14

#	Article	IF	CITATIONS
127	Peripheral Arterial Disease and Cardiovascular Risk. Angiology, 2015, 66, 708-710.	0.8	5
128	Remission of type 2 diabetes: is bariatric surgery ready for prime time?. Endocrine, 2015, 48, 417-421.	1.1	23
129	Comment on Tay et al. A Very Low-Carbohydrate, Low–Saturated Fat Diet for Type 2 Diabetes Management: A Randomized Trial. Diabetes Care 2014;37:2909–2918. Diabetes Care, 2015, 38, e64-e64.	4.3	2
130	Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmacogenomics and Personalized Medicine, 2014, 7, 129.	0.4	15
131	Diabetes and sexual dysfunction: current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2014, 7, 95.	1.1	157
132	Comment on Grunberger "Insulin Analogs—Are They Worth It? Yes!―Diabetes Care 2014;37:1767–1770 Davidson "Insulin Analogs—Is There a Compelling Case to Use Them? No!―Diabetes Care 2014;37:1771–1774. Diabetes Care, 2014, 37, e229-e230.	and 4.3	3
133	Opposite Influence of Light and Blindness on Pituitary–Gonadal Function. Frontiers in Endocrinology, 2014, 4, 205.	1.5	13
134	Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417. Diabetes Care, 2014, 37, e113-e113.	4.3	2
135	Comment on Home et al. Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. Diabetes Care 2014;37:1237–1245. Diabetes Care, 2014, 37, e183-e183.	4.3	2
136	Erectile Hydraulics: Maximizing Inflow While Minimizing Outflow. Journal of Sexual Medicine, 2014, 11, 1208-1220.	0.3	37
137	Mediterranean diet and type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2014, 30, 34-40.	1.7	66
138	The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. Cardiovascular Diabetology, 2014, 13, 140.	2.7	58
139	Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open, 2014, 4, e005442-e005442.	0.8	56
140	The Association Between Metabolic Syndrome and Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2014, 48, 742-743.	1.1	2
141	Use of serum pituitary antibodies to improve the diagnosis of hypophysitis. Expert Review of Endocrinology and Metabolism, 2014, 9, 465-476.	1.2	3
142	Sexual Activity in Midlife Women and Beyond. JAMA Internal Medicine, 2014, 174, 1203.	2.6	2
143	Acarbose vs metformin for new-onset type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2014, 2, 104.	5.5	4
144	Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine, 2014, 45, 28-36.	1.1	123

#	Article	IF	Citations
145	Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine, 2014, 46, 39-42.	1.1	22
146	Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors. Endocrine, 2014, 46, 43-51.	1.1	44
147	New guidelines for metabolic targets in diabetes: clinician's opinion does matter. Endocrine, 2014, 46, 431-434.	1.1	5
148	Healthy lifestyle for metabolic health: no more excuse!. Endocrine, 2014, 46, 176-178.	1.1	14
149	Metabolic syndrome and cancer: holistic or reductionist?. Endocrine, 2014, 45, 362-364.	1.1	31
150	The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?. Expert Opinion on Biological Therapy, 2014, 14, 799-808.	1.4	19
151	Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI. Endocrine, 2014, 46, 256-262.	1.1	32
152	Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine, 2014, 47, 107-116.	1.1	112
153	Cardiovascular guidelines: separate career may help attenuate controversy. Cardiovascular Diabetology, 2014, 13, 66.	2.7	2
154	The effect of Mediterranean diet on the development of type 2 diabetes mellitus: A meta-analysis of 10 prospective studies and 136,846 participants. Metabolism: Clinical and Experimental, 2014, 63, 903-911.	1.5	194
155	The Effects of a Mediterranean Diet on the Need for Diabetes Drugs and Remission of Newly Diagnosed Type 2 Diabetes: Follow-up of a Randomized Trial. Diabetes Care, 2014, 37, 1824-1830.	4.3	149
156	Management of hyperglycemia in type 2 diabetes: evidence and uncertainty. Cardiovascular Diabetology, 2013, 12, 81.	2.7	10
157	Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine, 2013, 44, 634-647.	1.1	152
158	Should we abandon statins in the prevention of bone fractures?. Endocrine, 2013, 44, 326-333.	1.1	31
159	Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?. Endocrine, 2013, 44, 343-345.	1.1	20
160	Mediterranean diet and metabolic syndrome: An updated systematic review. Reviews in Endocrine and Metabolic Disorders, 2013, 14, 255-263.	2.6	106
161	Fracture Risk and Bone Mineral Density in Metabolic Syndrome: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3306-3314.	1.8	30
162	Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis. Journal of Endocrinological Investigation, 2013, 36, 132-139.	1.8	112

#	Article	IF	CITATIONS
163	Comment on: Wing et al. Effect of Intensive Lifestyle Intervention on Sexual Dysfunction in Women With Type 2 Diabetes: Results From an Ancillary Look AHEAD Study. Diabetes Care 2013;36:2937–2944. Diabetes Care, 2013, 36, e190-e190.	4.3	1
164	Metabolic syndrome and postmenopausal breast cancer. Menopause, 2013, 20, 1301-1309.	0.8	110
165	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy & mp;ndash; focus on alogliptin. Drug Design, Development and Therapy, 2013, 7, 989.	2.0	41
166	Female sexual dysfunction in women with thyroid disorders. Journal of Endocrinological Investigation, 2013, 36, 729-33.	1.8	20
167	Circulating endothelial progenitor cells in acromegaly. Journal of Endocrinological Investigation, 2013, 36, 825-30.	1.8	4
168	Comment on: Wheeler et al. Macronutrients, Food Groups, and Eating Patterns in the Management of Diabetes: A Systematic Review of the Literature, 2010. Diabetes Care 2012;35:434-445. Diabetes Care, 2012, 35, e51-e51.	4.3	4
169	Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes. Diabetes Care, 2012, 35, 2698-2705.	4.3	11
170	Humalog (lispro) for type 2 diabetes. Expert Opinion on Biological Therapy, 2012, 12, 1541-1550.	1.4	10
171	Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. Expert Opinion on Biological Therapy, 2012, 12, 209-221.	1.4	18
172	Lifestyle for Erectile Dysfunction: A Good Choice. Archives of Internal Medicine, 2012, 172, 296.	4.3	3
173	HbA1c targets for type 2 diabetes: How many, …how far!. Diabetes Research and Clinical Practice, 2012, 96, 414-415.	1.1	6
174	Lifestyle and metabolic approaches to maximizing erectile and vascular health. International Journal of Impotence Research, 2012, 24, 61-68.	1.0	52
175	Metabolic Syndrome and Risk of Cancer. Diabetes Care, 2012, 35, 2402-2411.	4.3	900
176	Cardiometabolic Risk and Female Sexual Health: The Princeton III Summary (CME). Journal of Sexual Medicine, 2012, 9, 641-651.	0.3	109
177	Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes, Obesity and Metabolism, 2012, 14, 228-233.	2.2	119
178	Increased consumption of green leafy vegetables, but not fruit, vegetables or fruit and vegetables combined, is associated with reduced incidence of type 2 diabetes. Evidence-Based Medicine, 2011, 16, 27-28.	0.6	12
179	Lifestyle/Dietary Recommendations for Erectile Dysfunction and Female Sexual Dysfunction. Urologic Clinics of North America, 2011, 38, 293-301.	0.8	21
180	The Effect of Mediterranean Diet on Metabolic Syndrome and its Components. Journal of the American College of Cardiology, 2011, 57, 1299-1313.	1.2	917

#	Article	IF	Citations
181	Mediterranean Diet and Weight Loss: Meta-Analysis of Randomized Controlled Trials. Metabolic Syndrome and Related Disorders, 2011, 9, 1-12.	0.5	275
182	Clinical Inertia as a Clinical Safeguard. JAMA - Journal of the American Medical Association, 2011, 305, 1591.	3.8	74
183	Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review. Diabetes Research and Clinical Practice, 2011, 92, 1-10.	1.1	50
184	Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes-a randomized controlled trial. Diabetes, Obesity and Metabolism, 2011, 13, 439-445.	2.2	63
185	Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2011, 13, 594-603.	2.2	92
186	Obesity, the Metabolic Syndrome, and Sexual Dysfunction in Men. Clinical Pharmacology and Therapeutics, 2011, 90, 169-173.	2.3	55
187	Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. Journal of Diabetes and Its Complications, 2011, 25, 275-281.	1.2	17
188	The Link Between Erectile and Cardiovascular Health: The Canary in the Coal Mine. American Journal of Cardiology, 2011, 108, 599-606.	0.7	77
189	GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2011, 27, 1519-1528.	0.9	44
190	Dietary factors and low-grade inflammation in relation to overweight and obesity. British Journal of Nutrition, 2011, 106, S5-S78.	1.2	816
191	The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance―to Glucagon-Like Peptide 1 in Diabetes. Diabetes Care, 2011, 34, 697-702.	4.3	119
192	Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of & Type 2 Diabetes. Diabetes Care, 2011, 34, 510-517.	4.3	116
193	Clinical Inertia and Uncertainty in Medicine—Reply. JAMA - Journal of the American Medical Association, 2011, 306, 383.	3.8	6
194	Long-Term Effect of Mediterranean-Style Diet and Calorie Restriction on Biomarkers of Longevity and Oxidative Stress in Overweight Men. Cardiology Research and Practice, 2011, 2011, 1-5.	0.5	37
195	Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials. Metabolic Syndrome and Related Disorders, 2011, 9, 167-176.	0.5	2
196	Original Researchâ€"Outcomes Assessment: Development and Validation of a 6-Item Version of the Female Sexual Function Index (FSFI) as a Diagnostic Tool for Female Sexual Dysfunction. Journal of Sexual Medicine, 2010, 7, 1139-1146.	0.3	215
197	ORIGINAL RESEARCHâ€"ERECTILE DYSFUNCTION: Adherence to Mediterranean Diet and Erectile Dysfunction in Men with Type 2 Diabetes. Journal of Sexual Medicine, 2010, 7, 1911-1917.	0.3	49
198	ORIGINAL RESEARCH—WOMEN'S SEXUAL HEALTH: Adherence to Mediterranean Diet and Sexual Function in Women with Type 2 Diabetes. Journal of Sexual Medicine, 2010, 7, 1883-1890.	0.3	44

#	Article	IF	Citations
199	Dietary Factors, Mediterranean Diet and Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 2338-2345.	0.3	58
200	Determinants of female sexual dysfunction in type 2 diabetes. International Journal of Impotence Research, 2010, 22, 179-184.	1.0	144
201	Dietary Glycemic Index and Glycemic Load Are Associated with Metabolic Control in Type 2 Diabetes: The CAPRI Experience. Metabolic Syndrome and Related Disorders, 2010, 8, 255-261.	0.5	14
202	Lifestyle and Adiponectin Level: Four-Year Follow-up of Controlled Trials. Archives of Internal Medicine, 2010, 170, 1270.	4.3	4
203	Prevention of Type 2 Diabetes by Dietary Patterns: A Systematic Review of Prospective Studies and Meta-Analysis. Metabolic Syndrome and Related Disorders, 2010, 8, 471-476.	0.5	109
204	Determinants of erectile dysfunction in type 2 diabetes. International Journal of Impotence Research, 2010, 22, 204-209.	1.0	141
205	Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review. Diabetes Research and Clinical Practice, 2010, 89, 97-102.	1.1	170
206	Interleukin-20 circulating levels in obese women: Effect of weight loss. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 180-185.	1.1	18
207	Mediterranean Diet and the Metabolic Syndrome: The End of the Beginning. Metabolic Syndrome and Related Disorders, 2010, 8, 197-200.	0.5	33
208	Effects of Intensive Lifestyle Changes on Erectile Dysfunction in Men. Journal of Sexual Medicine, 2009, 6, 243-250.	0.3	103
209	Circulating CD34+KDR+ Endothelial Progenitor Cells Correlate with Erectile Function and Endothelial Function in Overweight Men. Journal of Sexual Medicine, 2009, 6, 107-114.	0.3	60
210	Hyperlipidemia and Sexual Function in Premenopausal Women. Journal of Sexual Medicine, 2009, 6, 1696-1703.	0.3	45
211	Which diet is best for diabetes?. Diabetologia, 2009, 52, 988-989.	2.9	5
212	Adherence to a Mediterranean diet and glycaemic control in Type 2 diabetes mellitus. Diabetic Medicine, 2009, 26, 900-907.	1.2	84
213	Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Annals of Internal Medicine, 2009, 151, 306.	2.0	380
214	Lifestyle approach for type 2 diabetes and metabolic syndrome. Current Atherosclerosis Reports, 2008, 10, 523-528.	2.0	20
215	Phenotypic Assessment of Endothelial Microparticles in Diabetic and Nondiabetic Men with Erectile Dysfunction. Journal of Sexual Medicine, 2008, 5, 1436-1442.	0.3	41
216	Post-Meal Glucose Peaks at Home Associate with Carotid Intima-Media Thickness in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1345-1350.	1.8	152

#	Article	IF	Citations
217	Obesity and sexual dysfunction, male and female. International Journal of Impotence Research, 2008, 20, 358-365.	1.0	126
218	Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control. Annals of Internal Medicine, 2008, 149, 531.	2.0	49
219	Are there specific treatments for the metabolic syndrome?. American Journal of Clinical Nutrition, 2008, 87, 8-11.	2.2	68
220	Mediterranean diet and metabolic diseases. Current Opinion in Lipidology, 2008, 19, 63-68.	1.2	175
221	Association of body weight with sexual function in women. International Journal of Impotence Research, 2007, 19, 353-357.	1.0	205
222	Endothelial microparticles correlate with erectile dysfunction in diabetic men. International Journal of Impotence Research, 2007, 19, 161-166.	1.0	52
223	Low-Carbohydrate Diet and Coronary Heart Disease in Women. New England Journal of Medicine, 2007, 356, 750-752.	13.9	18
224	Mediterranean diet improves sexual function in women with the metabolic syndrome. International Journal of Impotence Research, 2007, 19, 486-491.	1.0	58
225	Diet and the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2007, 5, 291-296.	0.5	34
226	Mediterranean diet and the metabolic syndrome. Molecular Nutrition and Food Research, 2007, 51, 1268-1274.	1.5	62
227	Quantitative Sensory and Autonomic Testing in Nondiabetic Women with Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 1367-1372.	0.3	17
228	Mediterranean diet, endothelial function and vascular inflammatory markers. Public Health Nutrition, 2006, 9, 1073-1076.	1.1	75
229	Re: Prevalence and Risk Factors for Female Sexual Dysfunction in Turkish Women. Journal of Urology, 2006, 176, 840-841.	0.2	6
230	The Effects of Diet on Inflammation. Journal of the American College of Cardiology, 2006, 48, 677-685.	1.2	654
231	Diet and inflammation: a link to metabolic and cardiovascular diseases. European Heart Journal, 2006, 27, 15-20.	1.0	187
232	Oxidative stress in the metabolic syndrome. Journal of Endocrinological Investigation, 2006, 29, 791-795.	1.8	80
233	Whole-grain intake cools down inflammation. American Journal of Clinical Nutrition, 2006, 83, 1440-1441.	2.2	18
234	Role of Adipokines in the Obesity???Inflammation Relationship: The Effect of Fat Removal. Plastic and Reconstructive Surgery, 2006, 118, 1048-1057.	0.7	72

#	Article	IF	Citations
235	Dietary factors in erectile dysfunction. International Journal of Impotence Research, 2006, 18, 370-374.	1.0	48
236	Mediterranean diet improves erectile function in subjects with the metabolic syndrome. International Journal of Impotence Research, 2006, 18, 405-410.	1.0	133
237	Endothelial Microparticles Correlate with Endothelial Dysfunction in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3676-3679.	1.8	140
238	Pioglitazone Reduces Endothelial Microparticles in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1926-1926.	1.1	35
239	Sexual dysfunction and the Mediterranean diet. Public Health Nutrition, 2006, 9, 1118-1120.	1.1	23
240	The metabolic syndrome: a cause of sexual dysfunction in women. International Journal of Impotence Research, 2005, 17, 224-226.	1.0	96
241	Obesity, the metabolic syndrome, and sexual dysfunction. International Journal of Impotence Research, 2005, 17, 391-398.	1.0	177
242	Inflammation Warms Up the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e143.	1.1	40
243	Fitness Versus Fatness: the Debate Continues. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e20-1; author reply e20-1.	1.1	6
244	High Proportions of Erectile Dysfunction in Men With the Metabolic Syndrome. Diabetes Care, 2005, 28, 1201-1203.	4. 3	231
245	Sexual Dysfunction in Women With the Metabolic Syndrome. Diabetes Care, 2005, 28, 756-756.	4.3	35
246	Metabolic Effects of Liposuction — Yes or No?. New England Journal of Medicine, 2004, 351, 1354-1357.	13.9	23
247	Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome. JAMA - Journal of the American Medical Association, 2004, 292, 1440.	3.8	1,819
248	Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men. JAMA - Journal of the American Medical Association, 2004, 291, 2978.	3.8	732
249	Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. Journal of Endocrinological Investigation, 2004, 27, 665-669.	1.8	130
250	Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus. Circulation, 2004, 110, 214-219.	1.6	406
251	The metabolic syndrome and inflammation: association or causation?. Nutrition, Metabolism and Cardiovascular Diseases, 2004, 14, 228-232.	1.1	185
252	Sympathovagal Balance, Nighttime Blood Pressure, and QT Intervals in Normotensive Obese Women. Obesity, 2003, 11, 653-659.	4.0	40

#	Article	IF	CITATIONS
253	Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women. Journal of Endocrinological Investigation, 2003, 26, RC5-RC8.	1.8	41
254	Association of Low Interleukin-10 Levels with the Metabolic Syndrome in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1055-1058.	1.8	281
255	Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women. JAMA - Journal of the American Medical Association, 2003, 289, 1799.	3.8	1,275
256	The Effect of Weight Loss on Endothelial Functions in Obesity: Response to Sciacqua et al Diabetes Care, 2003, 26, 2968-2969.	4.3	7
257	Effect of dietary antioxidants on postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects. American Journal of Clinical Nutrition, 2003, 77, 139-143.	2.2	112
258	Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. American Journal of Clinical Nutrition, 2003, 78, 1135-1140.	2.2	205
259	Reduction of Inflammatory Cytokine Concentrations and Improvement of Endothelial Functions in Obese Women After Weight Loss Over One Year. Circulation, 2002, 105, 804-809.	1.6	932
260	Weight Loss Reduces Interleukin-18 Levels in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3864-3866.	1.8	218
261	FFAs and QT Intervals in Obese Women with Visceral Adiposity: Effects of Sustained Weight Loss Over 1 Year. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2080-2083.	1.8	59
262	Mediterranean diet and prevention of coronary heart disease. Journal of Endocrinological Investigation, 2002, 25, 296-299.	1.8	9
263	Hyperglycemia and heart dysfunction: An oxidant mechanism contributing to heart failure in diabetes. Journal of Endocrinological Investigation, 2002, 25, 485-488.	1.8	6
264	Autonomic dysfunction associates with prolongation of QT intervals and blunted night BP in obese women with visceral obesity. Journal of Endocrinological Investigation, 2002, 25, RC32-RC35.	1.8	24
265	Obesity, cytokines and endothelial dysfunction: A link for the raised cardiovascular risk associated with visceral obesity. Journal of Endocrinological Investigation, 2002, 25, 646-649.	1.8	32
266	Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. Journal of the American College of Cardiology, 2002, 39, 1145-1150.	1.2	503
267	FFAs and QT Intervals in Obese Women with Visceral Adiposity: Effects of Sustained Weight Loss Over 1 Year. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2080-2083.	1.8	15
268	Weight Loss Reduces Interleukin-18 Levels in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3864-3866.	1.8	67